BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Earth Science Tech, Inc. Signs Agreement with TransBiotech

November 16, 2017 | News

Earth Science Tech, Inc. Signs Agreement with TransBiotech TransBiotech has vast expertise in analytic chemistry, which will help ETST pursue its goal of offering a stable product of very high quality.



Earth Science Tech, Inc. an innovative biotech company that operates in the fields of industrial hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, is proud to announce the signing of an agreement with TransBiotech a member of Québec Innove. TransBiotech will test the biological activity of the company's new nutraceutical products in vitro, and then in vivo in a second stage. TransBiotech has vast expertise in analytic chemistry, which will help ETST pursue its goal of offering a stable product of very high quality.

The results the TransBiotech labs obtain from tests on formulas based on ETST's International Provisional Patent Application will greatly help the acquisition of full patent protection for the company's technology. The results will also support the development of these formulas into the creation of new prophylactic treatment for breast cancer and new treatment for other health issues such as metabolic or brain disorders, and Inflammatory Bowel Diseases.

TransBiotech can analyze and test ETST's nutraceuticals and functional foods by employing chemistry analysis, based on the measurement of antioxidant capacity (ORAC), analysis of polyphenols, flavonoids, and fatty acid profiles (including omega-3, omega-6, EPA, DHA), amino acids, monosaccharides, and others.

This level of scientific scrutiny and expertise is exactly what the company needs to become a leader in its fields. For example, TransBiotech can help analyze the medicinal plants that will be used in ETST products by characterizing and quantifying the active ingredients.

This new partnership constitutes the second phase of the development of manufacturing processes for the three already-prototyped provisional CBD-based nutraceutical products that ETST has in the pipeline. The first phase was announced recently. In this first phase, the company is working with CDBQ and TransBiotech's world-renowned R&D groups to develop new ideas and products like those developed in the joint venture with Bionatus.

In the next few days ETST will start working closely with Bionatus Pharmacognosique Laboratory Inc. As announced earlier the first goal of the joint venture is to improve Bionatus' BioToss and Propovit medicinal products and introduce them into North American markets. Bionatus Pharmacognosique Laboratory Inc. has now an office at CQIB, a large research center in Laval, Québec, which will be used to develop new products.

André Konan, PhD, Manager, R&D and Regulatory Affairs - Bionatus Pharmacognosique Inc) said: "In addition to the joint improvement of BioToss and Propovit, we expect our partnership with ETST to stimulate the development of other strategic projects that will bring to market additional innovative plant-derived products, nutraceuticals, herbal medicines, hybrids, and drug substances."